International Clinical Trial: A Study to Test How Well Different Doses of BI 4060107 Are Tolerated by People With Advanced Cancer (Solid Tumours)

Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07827144) titled 'A Study to Test How Well Different Doses of BI 4060107 Are Tolerated by People With Advanced Cancer (Solid Tumours)' on Sept. 14.

Study Type: Interventional

Study Design: Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: AIMEDBIO

Condition: Solid Tumours

Intervention: Biological: BI 4060107

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: September 30, 2026

Target Sample Size: 90

Countries of Recruitment: United States Australia France Japan South Korea Australia France Japan South ...